AI Science Tracker
EN

Mortality prediction with adjuvant tamoxifen in breast cancer: Machine learning-integrated explainable artificial intelligence and Bayesian model results.

Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain · 29 Apr 2026 · medicine

Discovery

Mortality prediction with adjuvant tamoxifen in breast cancer: Machine learning-integrated explainable artificial intelligence and Bayesian model results.

Source check: Source checked. Not independent scientific confirmation.

Finding: The publisher study evaluated machine-learning mortality predictions among breast-cancer patients receiving adjuvant tamoxifen; the conclusion is limited to that study cohort and validation design.

Technology: The paper evaluates machine-learning mortality prediction for breast-cancer patients receiving adjuvant tamoxifen.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
The paper evaluates machine-learning mortality prediction for breast-cancer patients receiving adjuvant tamoxifen.
Test and result
Study cohort and reported reference/validation are as described by the publisher; no clinical benefit or broader population performance is established.
Limitation / still unknown
External replication and real-world or clinical benefit were not established by the reviewed study
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13147516/ · https://pubmed.ncbi.nlm.nih.gov/42100630/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.